middle.news
BlinkLab Surpasses FDA Benchmarks, Expands Autism Trial Network Ahead of 2026 Push
8:54am on Friday 30th of January, 2026 AEDT
•
Healthcare
Read Story
BlinkLab Surpasses FDA Benchmarks, Expands Autism Trial Network Ahead of 2026 Push
8:54am on Friday 30th of January, 2026 AEDT
Key Points
U.S. autism pilot study achieves 83.7% sensitivity and 84.7% specificity
FDA confirms pivotal 510(k) trial design and recruitment strategy
Expansion to eight U.S. clinical sites including Rush University Medical Center
European ADHD study in final recruitment stages with 332 subjects tested
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Blinklab (ASX:BB1)
OPEN ARTICLE